MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

More women than ever are being screened for cervical cancer, suggesting a policy change made just a few years ago is having a ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, ...

On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between the US and China, where demand for its blockbuster Gardasil vaccine is ...

Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...